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Abstract 
Background: A positive association between the ABO blood types and survival has been suggested in several malig‑
nancies. The aim of this study was to assess the role of the ABO blood types in predicting the prognosis of Chinese 
patients with curatively resected non‑small cell lung cancer (NSCLC).
Methods: We retrospectively analyzed 1601 consecutive Chinese patients who underwent curative surgery for 
NSCLC between January 1, 2005 and December 31, 2009. The relationship between the ABO blood types and survival 
was investigated. In addition, univariate and multivariate analyses were performed.
Results: Group 1 (patients with the blood type O or B) had significantly prolonged overall survival (OS) compared 
with group 2 (patients with the blood type A or AB), with a median OS of 74.9 months versus 61.5 months [hazard 
ratio (HR) 0.83; 95% confidence interval (CI) 0.72–0.96; P = 0.015]. Additionally, group 1 had significantly longer dis‑
ease‑free survival (DFS; HR 0.86; 95% CI 0.76–0.98; P = 0.022) and locoregional relapse‑free survival (LRFS; HR 0.79; 95% 
CI 0.64–0.98; P = 0.024) than group 2. The association was not significantly modified by other risk factors for NSCLC, 
including smoking status, pathologic tumor‑node‑metastasis stage, pT category, pN category, and chemotherapy.
Conclusions: There is an association between the ABO blood types and the survival of Chinese patients with 
resected NSCLC. Patients with the blood type O or B had significantly prolonged OS, DFS, and LRFS compared with 
those with the blood type A or AB.
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Background
Globally, lung cancer remains the most common cancer 
for both men and women and accounts for 13% of total 
cases and 18% of total deaths [1]. Lung cancer has also 
been the top one malignancy in terms of incidence and 
mortality in China [2, 3]. Non-small cell lung cancer 
(NSCLC) accounts for 80%–85% of 1.1 million newly 
diagnosed lung cancer cases annually [4]. Although sur-
gical resection with curative intent was available, 40%–
75% of patients died within 5  years [5]. Understanding 
the etiology of this typically fatal disease and identifying 
novel prognostic factors are essential for early diagnosis, 
prognosis evaluation, and more appropriate treatment.
The ABO blood type is determined by terminal carbo-
hydrates expressed on red blood cells, which are attached 
to a protein backbone, the H antigen. The glycosyltrans-
ferase, which is encoded by the ABO gene on chromo-
some 9q34, can catalyze the transfer of donor sugars to 
the H antigen to form the ABO blood type antigens [6, 7]. 
A genome-wide association study (GWAS) of pancreatic 
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cancer identified a genetic variation in the ABO locus 
of 9q34 that was associated with susceptibility to pan-
creatic cancer [8, 9]. The positive association between 
the ABO blood types and survival has been suggested in 
several malignancies [10], including pancreatic cancer 
[11, 12], breast cancer [13, 14], renal cell carcinoma [15], 
nasopharyngeal carcinoma [16], and colon cancer [17]. 
Although the study by Lee et al. [18] investigated the sur-
vival of patients with curatively resected NSCLC within 
the context of the ABO blood types, the aim of their 
study was to investigate the prognostic role of the expres-
sion of blood group antigen A in tumor cells.
We conducted this study to investigate the relationship 
between the ABO blood types and the survival of patients 
who underwent primary curative resection. We also eval-
uated the associations between the ABO blood types and 
other clinicopathologic features of NSCLC to determine 
whether the ABO blood types are independent prognos-
tic factors. In the present paper, we report results from 
Chinese patients with curatively resected NSCLC.
Patients and methods
Patient selection and data collection
A retrospective analysis was performed on consecutive 
patients who underwent curative surgery for NSCLC 
at the Sun Yat-sen University Cancer Center between 
January 1, 2005 and December 31, 2009. This study was 
approved by the Medical Ethics Committee and Clini-
cal Trial Review Committee of this cancer center. All 
patients had postoperatively, pathologically confirmed 
NSCLC without previous therapy other than complete 
resection and neoadjuvant chemotherapy. The main 
exclusion criteria included incomplete resection, previ-
ous malignant disease, and perioperative death. Informed 
consent was obtained from all individual participants 
included in the study.
Data were collected from electronic and paper patient 
medical records, and survival data were obtained from 
the cancer center’s follow-up registry. The data collected 
included age, sex, Eastern Cooperative Oncology Group 
(ECOG) performance status, smoking status, pathology, 
tumor-node-metastasis (TNM) stage, dates of surgery 
and relapse/metastasis, and the ABO blood type. Patients 
with insufficient data were excluded from this study. All 
patients were restaged by using the 7th international sys-
tem for lung cancer staging [19].
Study endpoints
The following endpoints were estimated: overall survival 
(OS), defined as the interval from the date of surgery to 
the date of death from any cause; disease-free survival 
(DFS), defined as the interval from the date of surgery to 
the date of disease recurrence or death from any cause; 
and locoregional relapse-free survival (LRFS) and distant 
metastasis-free survival (DMFS), defined as the inter-
val from the date of surgery to the date of locoregional 
relapse and distant metastasis, respectively.
Statistical analysis
All endpoints were estimated by the Kaplan–Meier 
method and compared by using the log-rank test. Mul-
tivariate analyses were carried out by using the Cox pro-
portional hazards model to identify important prognostic 
factors for OS. All variables reaching a significance of 0.1 
in univariate analyses were tested in the Cox model. Two-
sided P values of <0.05 were considered statistically sig-
nificant. All analyses were performed using the SPSS16.0 
software (SPSS Inc., Chicago, IL, USA).
Results
Patient population
A total of 1601 patients with NSCLC who underwent 
curative resection were included in this study (Table  1; 
Fig. 1). In the present study, blood types A, B, O, and AB 
were reported in 27.7%, 26.5%, 39.2%, and 6.6% of the 
patients, respectively, which were similar to those fre-
quencies reported previously for the Guangdong popula-
tion (type A, 25.02%; type B, 25.91%; type O, 42.96%; and 
type AB, 6.11%) [20]. As shown in Table 1, there were no 
significant differences in the basic characteristics of our 
study population based on the blood type. Overall, more 
than one-half of the patients were presented with adeno-
carcinoma, and most of the patients were males. Current 
smokers made up approximately half of all patients.
Associations between the ABO blood type and survival
The median follow-up was 81.0 months [95% confidence 
interval (CI) 78.9–83.1 months] for the entire study pop-
ulation. By the time of analysis (January 15, 2015), 360 
instances of locoregional relapse, 371 instances of distant 
metastases, and 810 instances of death had occurred. The 
median OSs for patients with blood types O, B, A, and 
AB were 75.4, 72.9, 62.6, and 56.5  months, respectively 
(P  =  0.083; Fig.  2a); the median DFSs were 48.9, 49.3, 
37.9, and 33.8  months for those with blood types O, B, 
A, and AB, respectively (P =  0.128, Fig.  2b). We found 
that patients with the blood type O or B had longer OS 
and DFS compared with those with the blood type A or 
AB, whereas OS and DFS were similar between patients 
with the blood types O and B as well as between those 
with the blood types A and AB. Therefore, we divided the 
entire cohort into group 1 (patients with the blood type 
O or B) and group 2 (patients with the blood type A or 
AB).
The OS, DFS, LRFS, and DMFS curves are shown in 
Fig. 3. Group 1 had significantly prolonged OS compared 
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Table 1 Basic characteristics in distinct ABO blood type groups of patients with non-small cell lung cancer (NSCLC)
Characteristic ABO blood type P valuea
O A B AB
Total (cases) 627 443 425 106
Age
 Median (years) 59 59 59 59
 Range (years) 30–82 24–80 19–84 23–81
 <55 years [cases (%)] 156 (25.2) 135 (31.8) 207 (33.0) 32 (30.2) 0.11
 55–64 years [cases (%)] 137 (30.9) 171 (40.2) 239 (38.1) 43 (40.6)
 >64 years [cases (%)] 150 (33.9) 119 (28.0) 181 (28.9) 31 (29.2)
Sex [cases (%)] 0.20
 Males 451 (71.9) 329 (74.3) 297 (69.9) 81 (76.4)
 Females 176 (28.1) 114 (25.7) 128 (30.1) 25 (23.6)
ECOG PS score [cases (%)] 0.94
 0 305 (48.6) 211 (47.6) 199 (46.8) 52 (49.1)
 1 322 (51.4) 232 (52.4) 226 (53.2) 54 (50.9)
Smoking status [cases (%)] 0.21
 Never 243 (38.8) 177 (40.0) 185 (43.5) 37 (34.9)
 Former 74 (11.8) 59 (13.3) 35 (8.2) 13 (12.3)
 Current 310 (49.4) 207 (46.7) 205 (48.2) 56 (52.8)
Pathology [cases (%)] 0.67
 Squamous cell carcinoma 242 (38.6) 149 (33.6) 142 (33.4) 38 (35.8)
 Adenocarcinoma 327 (52.2) 256 (57.8) 250 (58.8) 58 (54.7)
 Adenosquamous carcinoma 41 (6.5) 24 (5.4) 21 (4.9) 7 (6.6)
 Others 17 (2.8) 14 (3.2) 12 (2.8) 3 (1.8)
pT category [cases (%)] 0.80
 1 112 (17.9) 81 (18.3) 68 (16.0) 17 (16.0)
 2 393 (62.7) 274 (61.9) 288 (67.8) 68 (64.2)
 3 70 (11.2) 50 (11.3) 43 (10.1) 14 (13.2)
 4 52 (8.3) 38 (8.6) 26 (6.1) 7 (6.6)
pN category [cases (%)] 0.62
 0 372 (59.3) 239 (54.0) 232 (54.6) 62 (58.5)
 1 77 (12.3) 60 (13.5) 62 (14.6) 14 (13.2)
 2 178 (28.4) 144 (32.5) 131 (30.8) 30 (28.3)
pTNM stage [cases (%)] 0.88
 Ia 80 (12.8) 58 (13.1) 52 (12.2) 13 (12.3)
 Ib 231 (36.8) 144 (32.5) 155 (36.5) 37 (34.9)
 IIa 18 (2.9) 11 (2.5) 10 (2.4) 1 (0.9)
 IIb 91 (14.5) 62 (14.0) 59 (13.9) 20 (18.9)
 IIIa 207 (33.0) 168 (37.9) 149 (35.0) 35 (33.0)
Surgery type [cases (%)] 0.97
 Lobectomy 506 (80.7) 356 (80.4) 344 (80.9) 87 (82.1)
 Pneumonectomy 96 (15.3) 66 (14.9) 67 (15.8) 15 (14.2)
 Others 25 (4.0) 21 (4.7) 14 (3.3) 4 (3.7)
Chemotherapy [cases (%)] 0.81
 Neoadjuvant + adjuvant 14 (2.2) 13 (2.9) 13 (3.1) 3 (2.8)
 Neoadjuvant only 19 (3.0) 11 (2.5) 11 (2.6) 6 (5.7)
 Adjuvant only 389 (62.0) 287 (64.8) 272 (64.0) 66 (62.3)
 No 205 (32.7) 132 (29.8) 129 (30.4) 31 (29.2)
ECOG PS Eastern Cooperative Oncology Group performance status, pT category pathologic tumor category, pN category pathologic node category, pTNM stage 
pathologic tumor-node-metastasis stage
a χ2 test (multigroup comparison)
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with group 2, with a median OS of 74.9  months com-
pared with 61.5 months, respectively [hazard ratio (HR) 
0.83; 95% CI 0.72–0.96; P = 0.015; Fig. 3a]. Additionally, 
group 1 had a significantly longer DFS (HR 0.86; 95% CI 
0.76–0.98; P = 0.022; Fig. 3b) and LRFS (HR 0.79; 95% CI 
0.64–0.98; P = 0.024; Fig. 3c) than group 2. However, no 
significant difference was observed for DMFS between 
group 1 and group 2 (HR 0.89; 95% CI 0.72–1.10; 
P = 0.294; Fig. 3d).
The association of OS with clinicopathologic character-
istics was further analyzed using univariate and multivar-
iate analyses. In the univariate analysis, males, smoking 
history, pT category of 3/4, pN category of 1/2, stage 
IIIA, pneumonectomy, no chemotherapy, and the blood 
type A/AB were identified as negative prognostic factors. 
When these variables were further analyzed in the mul-
tivariate analysis, we found that smoking status, pT cat-
egory, pN category, pathologic tumor-node-metastasis 
(pTNM) stage, chemotherapy, and blood group had sig-
nificant HRs, indicating that they were significant predic-
tors of survival (Table 2).
Discussion
Recently, the association between the ABO blood type 
and survival of cancer patients has drawn much attention. 
When this study was designed, the association between 
the ABO blood type and survival of patients with cura-
tively resected NSCLC had not yet been explored. In this 
retrospective study of Chinese patients with completely 
resected NSCLC, patients with the blood type O or B had 
longer OS than those with the blood type A or AB. The 
blood type O or B was also associated with prolonged 
DFS and LRFS.
Our results of the association between the blood type 
O and patient survival are consistent with previous stud-
ies on other malignancies. The survival advantage of 
patients with the blood type O has been reported in pan-
creatic cancer [11, 12], breast cancer [13, 14], renal cell 
carcinoma [15], and nasopharyngeal carcinoma [16]. The 
blood type O appears to be a protective factor in the pre-
vention of tumor development [21]. Our results of the 
association of the blood type A with patient survival are 
in close agreement with the results from previous stud-
ies. The blood type A has been reported to be associated 
with poor prognosis in patients with pancreatic cancer 
[11], nasopharyngeal carcinoma [16], and colon cancer 
[17]. However, controversy still exists about the relation 
between the ABO blood type and patient survival because 
many publications reported negative results [22–26]. As 
our study was completed, the first report concerning the 
Fig. 1 The process of patient selection in this study. A total of 1601 patients with non‑small cell lung cancer who underwent curative resection 
were included in this study
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association between the ABO blood type and survival of 
patients with resected NSCLC was published [27]. The 
results of that study showed that the ABO blood type was 
an independent prognostic factor for resected NSCLC, 
and the blood group A antigen might be associated with 
poor prognosis of patients with resected NSCLC. The 
number of patients was relatively small (n  =  333), and 
some patients did not undergo complete resection in 
their study [27]. In our study, by contrast, the number of 
patients was relatively large (n = 1601), and all patients 
received curative resection for NSCLC.
Although the associations of the ABO blood type with 
cancer risk and survival have been reported in several 
malignancies [11–17], the genetic or biological mecha-
nisms underlying the associations remain unclear. The 
ABO gene encodes three glycosyltransferases, which 
attach N-acetylgalactosamine, d-galactose, and no sugar 
residue to the H antigen backbone to form blood types 
A, B, and O, respectively [6]. In addition to their expres-
sion on the surface of red blood cells, ABO blood group 
antigens are expressed on the surface of cells from the 
gastrointestinal tract, urogenital tract, bronchopulmo-
nary duct, skin, and breast duct [28, 29]. Loss of blood 
group antigen A/B expression on cancer cells is regu-
lated by hypermethylation of the ABO gene promoter, 
which is an early event in tumor development [30]. Loss 
of ABO blood group antigens from tumor cells is asso-
ciated with poor prognosis and increased metastatic 
potential in NSCLC [18, 31, 32]. Lee et al. [18] reported 
that the 28 patients with the blood type A or AB who had 
antigen A-negative tumors had significantly shorter sur-
vival than the 43 patients with the blood type A or AB 
who had antigen A-positive tumors and the 93 patients 
with the blood type O or B free of antigen A (median 
survival: 15 months versus 71 and 39 months, P < 0.001 
and P = 0.002, respectively). These results may partially 
explain the positive association between the blood type A 
and poor prognosis in patients with NSCLC.
Other potential mechanisms underlying the associa-
tion between the ABO blood types and patient survival 
include the host inflammatory state. Single nucleotide 
polymorphisms (SNPs) at the ABO locus have been 
reported to be associated with circulating levels of tumor 
necrosis factor-alpha (TNFα), soluble intracellular adhe-
sion molecule-1 (sICAM-1), E-selectin, and P-selectin 
[33–36]. These serum molecules are associated with 
inflammatory responses that are associated with the 
processes of angiogenesis, tumor growth, invasion, and 
migration. Tumor development is induced by the inflam-
matory microenvironment, which consists of inflamma-
tory cells and inflammatory mediators [37]. In particular, 
chronic inflammatory conditions predispose individuals 
to multiple types of malignancies and are linked to tumor 
invasion and metastasis [38]. The study by Suadicani et al. 
[39] suggested that the predictive values of inflamma-
tion-related risk factors for lung cancer mortality, includ-
ing smoking history, high salt consumption, high alcohol 
intake, and occupational dust exposure, were high among 
males with the blood type O compared with those with 
the blood type A. Thus, the inflammatory state could be 
a possible mechanism explaining the association between 
the ABO blood types and patient prognosis.
This study nevertheless has several limitations that 
should be noted. The crucial disadvantage of this analy-
sis is its retrospective nature. Because all patients were 
in-hospital, the possibility of selection bias cannot be 
ruled out. Another limitation is that East Asians con-
stitute most of our study population. The monotonic-
ity of the study population limits the universality of our 
results. Furthermore, only limited variables could be 
included in the multivariate analysis. Other factors, such 
Fig. 2 Kaplan–Meier survival curves stratified by the ABO blood type 
in 1601 patients with curatively resected non–small cell lung cancer. 
a Overall survival for four groups stratified by the ABO blood type. b 
Disease‑free survival for four groups stratified by the ABO blood type
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as anaplastic lymphoma kinase (ALK) rearrangement 
status, may be significant prognostic factors for NSCLC, 
but these data are not currently available. Future well-
designed studies that include diverse ethnic populations 
are warranted to further investigate the prognostic role 
of the ABO blood types in NSCLC patients. Addition-
ally, other potential clinicopathologic factors should be 
considered.
Fig. 3 Kaplan–Meier survival curves for 1601 patients with curatively resected non‑small cell lung cancer. a Group 1 (patients with the blood type 
O or B) had significantly prolonged overall survival compared with group 2 (patients with the blood type A or AB). b Group 1 had significantly pro‑
longed disease‑free survival compared with group 2. c Group 1 had significantly prolonged locoregional relapse‑free survival compared with group 
2. d No significant difference was observed for distant metastasis‑free survival between groups 1 and 2
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Conclusions
The ABO blood types were associated with survival 
of Chinese patients with curatively resected NSCLC. 
Patients with the blood type O or B had significantly 
longer OS, DFS, and LRFS than those with the blood type 
A or AB. Potential mechanisms underlying this associa-
tion warrant further investigation.
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